PTC Therapeutics, Inc. (PTCT) Spending and interest coverage
- R&D / revenue · 12 months: Value 42.95%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 8.39%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 42.95% | Research and development expense / revenue. Period ending 2026-06-30. $433.31M ÷ $1.01B × 100 ≈ 42.95% |
| Stock-based compensation / revenue · 12 months | 8.39% | Share-based compensation / revenue. Period ending 2026-06-30. $84.66M ÷ $1.01B × 100 ≈ 8.39% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 433.31M USD | Research and Development Expense |
| Revenue | 1.01B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 84.66M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 125.60M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $433.31M | $1.01B | $84.66M | $125.60M | (m) | 42.95% | 8.39% | (m) | (m) |
| 2026-03-31 | $447.15M | $827.11M | $79.91M | $-58.33M | (m) | 54.06% | 9.66% | (m) | (m) |
| 2025-12-31 | $455.25M | $1.73B | $74.55M | $866.93M | (m) | 26.31% | 4.31% | (m) | (m) |
| 2025-09-30 | $446.89M | $1.78B | $73.27M | $775.89M | (m) | 25.12% | 4.12% | (m) | (m) |
| 2025-06-30 | $508.14M | $1.76B | $73.60M | $718.37M | (m) | 28.79% | 4.17% | (m) | (m) |
| 2025-03-31 | $527.32M | $1.77B | $74.30M | $713.11M | (m) | 29.75% | 4.19% | (m) | (m) |
| 2024-12-31 | $534.48M | $806.78M | $74.61M | $-302.57M | (m) | 66.25% | 9.25% | (m) | (m) |
| 2024-09-30 | $531.06M | $900.66M | $73.88M | $-134.36M | (m) | 58.96% | 8.20% | (m) | (m) |
| 2024-06-30 | $533.86M | $900.45M | $81.07M | $-198.01M | (m) | 59.29% | 9.00% | (m) | (m) |
| 2024-03-31 | $587.57M | $927.56M | $91.20M | $-367.34M | (m) | 63.35% | 9.83% | (m) | (m) |
| 2023-12-31 | $666.56M | $937.82M | $101.64M | $-439.50M | (m) | 71.08% | 10.84% | (m) | (m) |
| 2023-09-30 | $733.90M | $798.18M | $112.47M | $-645.66M | (m) | 91.95% | 14.09% | (m) | (m) |
| 2023-06-30 | $735.15M | $818.73M | $114.20M | $-595.68M | (m) | 89.79% | 13.95% | (m) | (m) |
| 2023-03-31 | $706.54M | $770.45M | $112.56M | $-478.50M | (m) | 91.71% | 14.61% | (m) | (m) |
| 2022-12-31 | $651.50M | $698.80M | $110.33M | $-447.41M | (m) | 93.23% | 15.79% | (m) | (m) |
| 2022-09-30 | $612.65M | $696.62M | $109.22M | $-331.80M | (m) | 87.95% | 15.68% | (m) | (m) |
| 2022-06-30 | $578.03M | $618.24M | $106.43M | $-356.69M | (m) | 93.50% | 17.21% | (m) | (m) |
| 2022-03-31 | $546.25M | $569.39M | $104.39M | $-362.82M | (m) | 95.94% | 18.33% | (m) | (m) |
| 2021-12-31 | $540.68M | $538.59M | $103.51M | $-374.44M | (m) | 100.39% | 19.22% | (m) | (m) |
| 2021-09-30 | $508.85M | $492.23M | $98.69M | $-386.09M | (m) | 103.38% | 20.05% | (m) | (m) |
| 2021-06-30 | $471.01M | $471.89M | $89.60M | $-348.14M | (m) | 99.81% | 18.99% | (m) | (m) |
| 2021-03-31 | $522.05M | $430.45M | $80.81M | $-436.93M | (m) | 121.28% | 18.77% | (m) | (m) |
| 2020-12-31 | $477.64M | $380.77M | $70.33M | $-431.77M | (m) | 125.44% | 18.47% | (m) | (m) |
| 2020-09-30 | $441.46M | (m) | $60.38M | $-408.18M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $411.54M | (m) | $54.08M | $-413.52M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $294.99M | (m) | $48.09M | $-265.01M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $257.45M | (m) | $42.13M | $-241.16M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $229.27M | (m) | $39.15M | $-213.51M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $220.56M | (m) | $37.60M | $-201.27M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $193.19M | (m) | $34.77M | $-168.08M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $171.98M | $264.73M | $33.25M | $-115.69M | (m) | 64.96% | 12.56% | (m) | (m) |
| 2018-09-30 | $147.57M | (m) | $31.25M | $-65.10M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $123.23M | (m) | $29.48M | $-47.76M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $121.46M | $223.91M | $29.28M | $-54.68M | (m) | 54.24% | 13.08% | (m) | (m) |
| 2017-12-31 | $117.46M | $194.39M | $30.56M | $-64.29M | (m) | 60.42% | 15.72% | (m) | (m) |
| 2017-09-30 | $114.23M | $141.55M | $32.48M | $-94.73M | (m) | 80.70% | 22.95% | (m) | (m) |
| 2017-06-30 | $115.61M | $122.69M | $34.27M | $-95.91M | (m) | 94.23% | 27.93% | (m) | (m) |
| 2017-03-31 | $113.60M | $90.36M | $35.12M | $-119.97M | (m) | 125.72% | 38.87% | (m) | (m) |
| 2016-12-31 | $117.63M | $82.70M | $35.01M | $-132.06M | (m) | 142.23% | 42.33% | (m) | (m) |
| 2016-09-30 | $126.67M | $70.25M | $34.46M | $-155.27M | (m) | 180.32% | 49.05% | (m) | (m) |
| 2016-06-30 | $125.91M | $57.04M | $33.55M | $-165.44M | (m) | 220.75% | 58.83% | (m) | (m) |
| 2016-03-31 | $125.28M | $48.18M | $33.15M | $-167.50M | (m) | 260.02% | 68.80% | (m) | (m) |
| 2015-12-31 | $121.82M | $36.77M | $33.98M | $-167.13M | (m) | 331.33% | 92.42% | (m) | (m) |
| 2015-09-30 | $113.64M | $36.69M | $32.84M | $-151.16M | (m) | 309.73% | 89.49% | (m) | (m) |
| 2015-06-30 | $101.76M | $28.61M | $29.40M | $-136.53M | (m) | 355.73% | 102.78% | (m) | (m) |
| 2015-03-31 | $91.89M | $23.51M | $25.35M | $-123.27M | (m) | 390.84% | 107.84% | (m) | (m) |
| 2014-12-31 | $79.84M | $25.25M | $19.31M | $-99.41M | (m) | 316.25% | 76.49% | (m) | (m) |
| 2014-09-30 | $67.99M | $17.00M | $15.89M | $-85.28M | (m) | 399.96% | 93.48% | (m) | (m) |
| 2014-06-30 | $63.11M | $31.59M | $13.91M | $-61.95M | (m) | 199.75% | 44.02% | (m) | (m) |
| 2014-03-31 | $59.51M | $36.77M | $11.51M | $-51.03M | (m) | 161.83% | 31.30% | (m) | (m) |
| 2013-12-31 | $54.88M | $34.70M | $8.43M | $-45.40M | (m) | 158.16% | 24.29% | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $28.56M | (m) | $-29.16M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $46.14M | $33.95M | $2.29M | $-26.81M | (m) | 135.92% | 6.74% | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $58.68M | $105.41M | $2.82M | $30.58M | (m) | 55.66% | 2.67% | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |